The Food and Drug Administration (FDA) officially submitted a report to Congress discussing the state of the CBD marketplace on Wednesday, July 7th, 2020. The document summarized several studies the FDA has performed on the contents and quality of cannabis-derived products that it tested over the past six years. Last year, Congress attached congressional appropriations legislation to advance the FDA studies on cannabis. The report exhibited “significant inconsistencies between cannabinoids concentrations that are listed on labels and what the products actually contain”. Cannabis advocates have pointed out the need for FDA to establish federal and state regulations in order to ensure quality control in the market.

– Marijuana Moment, July 9th, 2020

Open article: